Sphingosine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (6)Transporters (1)

Targets (6)Transporters (1)Biointeractions (1)

Identification

Name

Sphingosine

Accession Number

DB03203 (EXPT02945)

Type

Small Molecule

Groups

Experimental

Description

An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Not Available

External IDs

Not Available

Product Ingredients

Not Available

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

NGZ37HRE42

CAS number

123-78-4

Weight

Average: 299.4919
Monoisotopic: 299.282429433

Chemical Formula

C₁₈H₃₇NO₂

InChI Key

WWUZIQQURGPMPG-KRWOKUGFSA-N

InChI

InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14+/t17-,18+/m0/s1

IUPAC Name

(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol

SMILES

[H]\C(CCCCCCCCCCCCC)=C(\[H])[C@@]([H])(O)[C@@]([H])(N)CO

Pharmacology

Indication

Not Available

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Glycolipid transfer protein	Protein	unknown	Not Available	Human	Q9NZD2	details
Genome polyprotein	Protein	unknown	Not Available	Poliovirus type 1 (strain Mahoney)	P03300	details
Genome polyprotein	Protein	unknown	Not Available	HRV-14	P03303	details
Genome polyprotein	Protein	unknown	Not Available	SVDV	P13900	details
Genome polyprotein	Protein	unknown	Not Available	Poliovirus type 3 (strains P3/Leon/37 and P3/Leon 12A[1]B)	P03302	details
Poliovirus receptor	Protein	unknown	Not Available	Human	P15151	details

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Acetaminophen	The serum concentration of Sphingosine can be increased when it is combined with Acetaminophen.	Approved
Afatinib	The serum concentration of Sphingosine can be increased when it is combined with Afatinib.	Approved
Albendazole	The serum concentration of Sphingosine can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldosterone	The serum concentration of Sphingosine can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Sphingosine can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Sphingosine can be increased when it is combined with Alfentanil.	Approved, Illicit
Amantadine	The serum concentration of Sphingosine can be increased when it is combined with Amantadine.	Approved
Aminohippuric acid	The serum concentration of Sphingosine can be increased when it is combined with Aminohippuric acid.	Approved
Amiodarone	The serum concentration of Sphingosine can be decreased when it is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Sphingosine can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Sphingosine can be increased when it is combined with Amlodipine.	Approved
Amprenavir	The serum concentration of Sphingosine can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Sphingosine can be increased when it is combined with Amsacrine.	Approved
Astemizole	The serum concentration of Sphingosine can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Sphingosine can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Sphingosine can be increased when it is combined with Atenolol.	Approved
Atorvastatin	The serum concentration of Sphingosine can be increased when it is combined with Atorvastatin.	Approved
Azelastine	The serum concentration of Sphingosine can be increased when it is combined with Azelastine.	Approved
Azithromycin	The serum concentration of Sphingosine can be increased when it is combined with Azithromycin.	Approved
Benzocaine	The serum concentration of Sphingosine can be increased when it is combined with Benzocaine.	Approved
Bepridil	The serum concentration of Sphingosine can be increased when it is combined with Bepridil.	Approved, Withdrawn
Biperiden	The serum concentration of Sphingosine can be increased when it is combined with Biperiden.	Approved
Bosutinib	The serum concentration of Sphingosine can be increased when it is combined with Bosutinib.	Approved
Bromocriptine	The serum concentration of Sphingosine can be increased when it is combined with Bromocriptine.	Approved, Investigational
Buprenorphine	The serum concentration of Sphingosine can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Sphingosine can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The serum concentration of Sphingosine can be increased when it is combined with Cabazitaxel.	Approved
Caffeine	The serum concentration of Sphingosine can be increased when it is combined with Caffeine.	Approved
Canagliflozin	The serum concentration of Sphingosine can be increased when it is combined with Canagliflozin.	Approved
Candesartan	The serum concentration of Sphingosine can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Sphingosine can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Sphingosine can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carvedilol	The serum concentration of Sphingosine can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Sphingosine can be increased when it is combined with Caspofungin.	Approved
Chloroquine	The serum concentration of Sphingosine can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorpromazine	The serum concentration of Sphingosine can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Sphingosine can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Sphingosine can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholesterol	The serum concentration of Sphingosine can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Sphingosine can be decreased when it is combined with Cholic Acid.	Approved
Cilazapril	The serum concentration of Sphingosine can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Sphingosine can be decreased when it is combined with Cimetidine.	Approved
Ciprofloxacin	The serum concentration of Sphingosine can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Citalopram	The serum concentration of Sphingosine can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Sphingosine can be increased when it is combined with Clarithromycin.	Approved
Clofazimine	The serum concentration of Sphingosine can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Sphingosine can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clotrimazole	The serum concentration of Sphingosine can be decreased when it is combined with Clotrimazole.	Approved, Vet Approved
Cobicistat	The serum concentration of Sphingosine can be increased when it is combined with Cobicistat.	Approved
Colchicine	The serum concentration of Sphingosine can be increased when it is combined with Colchicine.	Approved
Colforsin	The serum concentration of Sphingosine can be increased when it is combined with Colforsin.	Experimental
Crizotinib	The serum concentration of Sphingosine can be increased when it is combined with Crizotinib.	Approved
Cyclophosphamide	The serum concentration of Sphingosine can be increased when it is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Sphingosine can be decreased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Daclatasvir	The serum concentration of Sphingosine can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Sphingosine can be increased when it is combined with Dactinomycin.	Approved
Dasatinib	The serum concentration of Sphingosine can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Sphingosine can be decreased when it is combined with Daunorubicin.	Approved
Desipramine	The serum concentration of Sphingosine can be increased when it is combined with Desipramine.	Approved
Desloratadine	The serum concentration of Sphingosine can be increased when it is combined with Desloratadine.	Approved, Investigational
Dexamethasone	The serum concentration of Sphingosine can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dextromethorphan	The serum concentration of Sphingosine can be increased when it is combined with Dextromethorphan.	Approved
Diclofenac	The serum concentration of Sphingosine can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Digoxin	The serum concentration of Sphingosine can be decreased when it is combined with Digoxin.	Approved
Dihydroergotamine	The serum concentration of Sphingosine can be increased when it is combined with Dihydroergotamine.	Approved
Diltiazem	The serum concentration of Sphingosine can be increased when it is combined with Diltiazem.	Approved
Dipyridamole	The serum concentration of Sphingosine can be increased when it is combined with Dipyridamole.	Approved
Doxazosin	The serum concentration of Sphingosine can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Sphingosine can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Sphingosine can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Dronabinol	The serum concentration of Sphingosine can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The serum concentration of Sphingosine can be increased when it is combined with Dronedarone.	Approved
Elbasvir	The serum concentration of Sphingosine can be increased when it is combined with Elbasvir.	Approved
Enalapril	The serum concentration of Sphingosine can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enzalutamide	The serum concentration of Sphingosine can be increased when it is combined with Enzalutamide.	Approved
Ergonovine	The serum concentration of Sphingosine can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Sphingosine can be increased when it is combined with Ergotamine.	Approved
Erythromycin	The serum concentration of Sphingosine can be decreased when it is combined with Erythromycin.	Approved, Vet Approved
Estramustine	The serum concentration of Sphingosine can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Sphingosine can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Sphingosine can be decreased when it is combined with Estrone.	Approved
Etoposide	The serum concentration of Sphingosine can be increased when it is combined with Etoposide.	Approved
Etravirine	The serum concentration of Sphingosine can be increased when it is combined with Etravirine.	Approved
Felodipine	The serum concentration of Sphingosine can be increased when it is combined with Felodipine.	Approved, Investigational
Fentanyl	The serum concentration of Sphingosine can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The serum concentration of Sphingosine can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Sphingosine can be increased when it is combined with Fidaxomicin.	Approved
Fluconazole	The serum concentration of Sphingosine can be increased when it is combined with Fluconazole.	Approved
Fluoxetine	The serum concentration of Sphingosine can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Sphingosine can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Sphingosine can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Sphingosine can be increased when it is combined with Flurazepam.	Approved, Illicit
Fluvoxamine	The serum concentration of Sphingosine can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Gefitinib	The serum concentration of Sphingosine can be increased when it is combined with Gefitinib.	Approved, Investigational
Genistein	The serum concentration of Sphingosine can be increased when it is combined with Genistein.	Investigational
Glyburide	The serum concentration of Sphingosine can be increased when it is combined with Glyburide.	Approved
Gramicidin D	The serum concentration of Sphingosine can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The serum concentration of Sphingosine can be increased when it is combined with Grepafloxacin.	Withdrawn
Haloperidol	The serum concentration of Sphingosine can be increased when it is combined with Haloperidol.	Approved
Hydrocortisone	The serum concentration of Sphingosine can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Idelalisib	The serum concentration of Sphingosine can be increased when it is combined with Idelalisib.	Approved
Imatinib	The serum concentration of Sphingosine can be increased when it is combined with Imatinib.	Approved
Imipramine	The serum concentration of Sphingosine can be increased when it is combined with Imipramine.	Approved
Indinavir	The serum concentration of Sphingosine can be decreased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Sphingosine can be increased when it is combined with Indomethacin.	Approved, Investigational
Isavuconazonium	The serum concentration of Sphingosine can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Itraconazole	The serum concentration of Sphingosine can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Sphingosine can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Sphingosine can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Ketamine	The serum concentration of Sphingosine can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketoconazole	The serum concentration of Sphingosine can be increased when it is combined with Ketoconazole.	Approved, Investigational
Lansoprazole	The serum concentration of Sphingosine can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Sphingosine can be increased when it is combined with Lapatinib.	Approved, Investigational
Levofloxacin	The serum concentration of Sphingosine can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levothyroxine	The serum concentration of Sphingosine can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Sphingosine can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Liothyronine	The serum concentration of Sphingosine can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Sphingosine can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The serum concentration of Sphingosine can be increased when it is combined with Lisinopril.	Approved, Investigational
Lomitapide	The serum concentration of Sphingosine can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Sphingosine can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of Sphingosine can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Sphingosine can be increased when it is combined with Loratadine.	Approved
Losartan	The serum concentration of Sphingosine can be increased when it is combined with Losartan.	Approved
Lovastatin	The serum concentration of Sphingosine can be increased when it is combined with Lovastatin.	Approved, Investigational
Lumacaftor	The serum concentration of Sphingosine can be decreased when it is combined with Lumacaftor.	Approved
Maprotiline	The serum concentration of Sphingosine can be increased when it is combined with Maprotiline.	Approved
Mebendazole	The serum concentration of Sphingosine can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mefloquine	The serum concentration of Sphingosine can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Sphingosine can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meprobamate	The serum concentration of Sphingosine can be increased when it is combined with Meprobamate.	Approved, Illicit
Methadone	The serum concentration of Sphingosine can be increased when it is combined with Methadone.	Approved
Metoprolol	The serum concentration of Sphingosine can be increased when it is combined with Metoprolol.	Approved, Investigational
Mibefradil	The serum concentration of Sphingosine can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Sphingosine can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Sphingosine can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	The serum concentration of Sphingosine can be decreased when it is combined with Mifepristone.	Approved, Investigational
Mitomycin	The serum concentration of Sphingosine can be increased when it is combined with Mitomycin.	Approved
Mitoxantrone	The serum concentration of Sphingosine can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Morphine	The serum concentration of Sphingosine can be increased when it is combined with Morphine.	Approved, Investigational
Naltrexone	The serum concentration of Sphingosine can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Sphingosine can be increased when it is combined with Naringenin.	Experimental
Nefazodone	The serum concentration of Sphingosine can be decreased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Sphingosine can be decreased when it is combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Sphingosine can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Nicardipine	The serum concentration of Sphingosine can be increased when it is combined with Nicardipine.	Approved
Nifedipine	The serum concentration of Sphingosine can be decreased when it is combined with Nifedipine.	Approved
Nilotinib	The serum concentration of Sphingosine can be increased when it is combined with Nilotinib.	Approved, Investigational
Nisoldipine	The serum concentration of Sphingosine can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Sphingosine can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Sphingosine can be increased when it is combined with Nitrendipine.	Approved
Norethisterone	The serum concentration of Sphingosine can be decreased when it is combined with Norethisterone.	Approved
Omeprazole	The serum concentration of Sphingosine can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
P-Nitrophenol	The serum concentration of Sphingosine can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of Sphingosine can be increased when it is combined with Paclitaxel.	Approved, Vet Approved
Palmitic Acid	The serum concentration of Sphingosine can be increased when it is combined with Palmitic Acid.	Experimental
Pantoprazole	The serum concentration of Sphingosine can be increased when it is combined with Pantoprazole.	Approved
Paroxetine	The serum concentration of Sphingosine can be increased when it is combined with Paroxetine.	Approved, Investigational
Perindopril	The serum concentration of Sphingosine can be increased when it is combined with Perindopril.	Approved
Phenobarbital	The serum concentration of Sphingosine can be decreased when it is combined with Phenobarbital.	Approved
Pimozide	The serum concentration of Sphingosine can be increased when it is combined with Pimozide.	Approved
Platelet Activating Factor	The serum concentration of Sphingosine can be decreased when it is combined with Platelet Activating Factor.	Experimental
Ponatinib	The serum concentration of Sphingosine can be increased when it is combined with Ponatinib.	Approved
Posaconazole	The serum concentration of Sphingosine can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pravastatin	The serum concentration of Sphingosine can be increased when it is combined with Pravastatin.	Approved
Prazosin	The serum concentration of Sphingosine can be increased when it is combined with Prazosin.	Approved
Prednisone	The serum concentration of Sphingosine can be increased when it is combined with Prednisone.	Approved, Vet Approved
Probenecid	The serum concentration of Sphingosine can be increased when it is combined with Probenecid.	Approved
Progesterone	The serum concentration of Sphingosine can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Promethazine	The serum concentration of Sphingosine can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Sphingosine can be increased when it is combined with Propafenone.	Approved
Propranolol	The serum concentration of Sphingosine can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Sphingosine can be increased when it is combined with Protriptyline.	Approved
Quercetin	The serum concentration of Sphingosine can be increased when it is combined with Quercetin.	Experimental
Quinacrine	The serum concentration of Sphingosine can be increased when it is combined with Quinacrine.	Approved
Quinidine	The serum concentration of Sphingosine can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Sphingosine can be increased when it is combined with Quinine.	Approved
Ranitidine	The serum concentration of Sphingosine can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Sphingosine can be increased when it is combined with Ranolazine.	Approved, Investigational
Reboxetine	The serum concentration of Sphingosine can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Sphingosine can be increased when it is combined with Regorafenib.	Approved
Reserpine	The serum concentration of Sphingosine can be decreased when it is combined with Reserpine.	Approved
Rifampicin	The serum concentration of Sphingosine can be decreased when it is combined with Rifampicin.	Approved
Rilpivirine	The serum concentration of Sphingosine can be increased when it is combined with Rilpivirine.	Approved
Ritonavir	The serum concentration of Sphingosine can be decreased when it is combined with Ritonavir.	Approved, Investigational
Rolapitant	The serum concentration of Sphingosine can be increased when it is combined with Rolapitant.	Approved
Saquinavir	The serum concentration of Sphingosine can be decreased when it is combined with Saquinavir.	Approved, Investigational
Scopolamine	The serum concentration of Sphingosine can be increased when it is combined with Scopolamine.	Approved
Selegiline	The serum concentration of Sphingosine can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Sertraline	The serum concentration of Sphingosine can be increased when it is combined with Sertraline.	Approved
Simeprevir	The serum concentration of Sphingosine can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Sphingosine can be increased when it is combined with Simvastatin.	Approved
Sirolimus	The serum concentration of Sphingosine can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sorafenib	The serum concentration of Sphingosine can be increased when it is combined with Sorafenib.	Approved, Investigational
Spironolactone	The serum concentration of Sphingosine can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Sphingosine can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Sphingosine can be increased when it is combined with Staurosporine.	Experimental
Streptozocin	The serum concentration of Sphingosine can be decreased when it is combined with Streptozocin.	Approved
Sulfinpyrazone	The serum concentration of Sphingosine can be increased when it is combined with Sulfinpyrazone.	Approved
Sumatriptan	The serum concentration of Sphingosine can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Sphingosine can be increased when it is combined with Sunitinib.	Approved, Investigational
Tacrine	The serum concentration of Sphingosine can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The serum concentration of Sphingosine can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Sphingosine can be decreased when it is combined with Tamoxifen.	Approved
Taurocholic Acid	The serum concentration of Sphingosine can be increased when it is combined with Taurocholic Acid.	Experimental
Telmisartan	The serum concentration of Sphingosine can be increased when it is combined with Telmisartan.	Approved, Investigational
Temsirolimus	The serum concentration of Sphingosine can be increased when it is combined with Temsirolimus.	Approved
Terazosin	The serum concentration of Sphingosine can be increased when it is combined with Terazosin.	Approved
Terfenadine	The serum concentration of Sphingosine can be increased when it is combined with Terfenadine.	Withdrawn
Tesmilifene	The serum concentration of Sphingosine can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Sphingosine can be increased when it is combined with Testosterone.	Approved, Investigational
Ticagrelor	The serum concentration of Sphingosine can be increased when it is combined with Ticagrelor.	Approved
Tolvaptan	The serum concentration of Sphingosine can be increased when it is combined with Tolvaptan.	Approved
Trazodone	The serum concentration of Sphingosine can be decreased when it is combined with Trazodone.	Approved, Investigational
Trifluoperazine	The serum concentration of Sphingosine can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Sphingosine can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Sphingosine can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Sphingosine can be increased when it is combined with Trimipramine.	Approved
Venlafaxine	The serum concentration of Sphingosine can be increased when it is combined with Venlafaxine.	Approved
Verapamil	The serum concentration of Sphingosine can be decreased when it is combined with Verapamil.	Approved
Vinblastine	The serum concentration of Sphingosine can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Sphingosine can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Sphingosine can be increased when it is combined with Vinorelbine.	Approved, Investigational
Zimelidine	The serum concentration of Sphingosine can be increased when it is combined with Zimelidine.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Dennis Liotta, Alfred H. Merrill, "Method of preparing sphingosine derivatives." U.S. Patent US5110987, issued August, 1976.

US5110987

General References

Not Available

External Links

Resource	Link
KEGG Compound	C00319
ChemSpider	4444047
BindingDB	83205
ChEBI	16393
ChEMBL	CHEMBL67166
Therapeutic Targets Database	DNC001357
IUPHAR	2452
Guide to Pharmacology	2452
HET	SQS

ATC Codes

Not Available

AHFS Codes

Not Available

PDB Entries

1SX6

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	67 °C	PhysProp

Predicted Properties

Property	Value	Source
Water Solubility	0.0039 mg/mL	ALOGPS
logP	5.15	ALOGPS
logP	4.57	ChemAxon
logS	-4.9	ALOGPS
pKa (Strongest Acidic)	14.12	ChemAxon
pKa (Strongest Basic)	9.23	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	66.48 Å²	ChemAxon
Rotatable Bond Count	15	ChemAxon
Refractivity	91.89 m³·mol^-1	ChemAxon
Polarizability	39.37 Å³	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.995
Blood Brain Barrier	+	0.5839
Caco-2 permeable	-	0.573
P-glycoprotein substrate	Substrate	0.5295
P-glycoprotein inhibitor I	Non-inhibitor	0.9155
P-glycoprotein inhibitor II	Non-inhibitor	0.7564
Renal organic cation transporter	Non-inhibitor	0.8759
CYP450 2C9 substrate	Non-substrate	0.8247
CYP450 2D6 substrate	Non-substrate	0.706
CYP450 3A4 substrate	Non-substrate	0.7191
CYP450 1A2 substrate	Inhibitor	0.9106
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Inhibitor	0.8932
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.9151
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7332
Ames test	Non AMES toxic	0.7957
Carcinogenicity	Non-carcinogens	0.7754
Biodegradation	Ready biodegradable	0.748
Rat acute toxicity	1.6142 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8822
hERG inhibition (predictor II)	Non-inhibitor	0.854

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
GC-MS	GC-MS Spectrum - GC-MS (3 TMS)	splash10-0udi-1690000000-901fd6e5629da37ac9f1	View in MoNA
GC-MS	GC-MS Spectrum - GC-EI-TOF	splash10-0udi-0590000000-9720cbb900a4b9086b5c	View in MoNA
GC-MS	GC-MS Spectrum - GC-EI-TOF	splash10-0udi-0590000000-9720cbb900a4b9086b5c	View in MoNA
GC-MS	GC-MS Spectrum - GC-EI-TOF	splash10-0udi-0690000000-9ed3190e406f4e0b00e8	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QQ , positive	splash10-001i-0091000000-2b5eca8b8e37ffe56f2c	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organic nitrogen compounds

Sub Class

Organonitrogen compounds

Direct Parent

1,2-aminoalcohols

Alternative Parents

Secondary alcohols / Primary alcohols / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives

Substituents

Secondary alcohol / 1,2-aminoalcohol / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Primary alcohol / Organooxygen compound / Primary aliphatic amine / Alcohol

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

sphing-4-enine (CHEBI:16393 ) / Sphing-4-enines (Sphingosines) (C00319 ) / Sphing-4-enines (Sphingosines) (LMSP01010001 )

Targets

Details

1. Glycolipid transfer protein

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Lipid binding
Specific Function:: Accelerates the intermembrane transfer of various glycolipids. Catalyzes the transfer of various glycosphingolipids between membranes but does not catalyze the transfer of phospholipids. May be involved in the intracellular translocation of glucosylceramides.
Gene Name:: GLTP
Uniprot ID:: Q9NZD2
Molecular Weight:: 23849.6 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Details

2. Genome polyprotein

Kind: Protein
Organism: Poliovirus type 1 (strain Mahoney)
Pharmacological action: unknown

General Function:: Structural molecule activity
Specific Function:: Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor PVR to provide virion attachment to targe...
Gene Name:: Not Available
Uniprot ID:: P03300
Molecular Weight:: 246538.14 Da

References

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Details

3. Genome polyprotein

Kind: Protein
Organism: HRV-14
Pharmacological action: unknown

General Function:: Structural molecule activity
Specific Function:: Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host ICAM1 to provide virion attachment to target host cells...
Gene Name:: Not Available
Uniprot ID:: P03303
Molecular Weight:: 242989.38 Da

References

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Details

4. Genome polyprotein

Kind: Protein
Organism: SVDV
Pharmacological action: unknown

General Function:: Structural molecule activity
Specific Function:: Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host CXADR to provide virion attachment to target host cells...
Gene Name:: Not Available
Uniprot ID:: P13900
Molecular Weight:: 243363.48 Da

References

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Details

5. Genome polyprotein

Kind: Protein
Organism: Poliovirus type 3 (strains P3/Leon/37 and P3/Leon 12A[1]B)
Pharmacological action: unknown

General Function:: Structural molecule activity
Specific Function:: Capsid protein VP1: Forms an icosahedral capsid of pseudo T=3 symmetry with capsid proteins VP2 and VP3. The capsid is 300 Angstroms in diameter, composed of 60 copies of each capsid protein and enclosing the viral positive strand RNA genome. Capsid protein VP1 mainly forms the vertices of the capsid. Capsid protein VP1 interacts with host cell receptor to provide virion attachment to target ho...
Gene Name:: Not Available
Uniprot ID:: P03302
Molecular Weight:: 246162.675 Da

References

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Details

6. Poliovirus receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Virus receptor activity
Specific Function:: Mediates NK cell adhesion and triggers NK cell effector functions. Binds two different NK cell receptors: CD96 and CD226. These interactions accumulates at the cell-cell contact site, leading to the formation of a mature immunological synapse between NK cell and target cell. This may trigger adhesion and secretion of lytic granules and IFN-gamma and activate cytoxicity of activated NK cells. Ma...
Gene Name:: PVR
Uniprot ID:: P15151
Molecular Weight:: 45302.3 Da

References

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Molecular Weight:: 141477.255 Da

References

Sugawara T, Kinoshita M, Ohnishi M, Tsuzuki T, Miyazawa T, Nagata J, Hirata T, Saito M: Efflux of sphingoid bases by P-glycoprotein in human intestinal Caco-2 cells. Biosci Biotechnol Biochem. 2004 Dec;68(12):2541-6. [PubMed:15618625 ]

Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 20:45

Get DrugBank to go!

Structure for DB03203 (Sphingosine)

Targets

References

References

References

References

References

References

Transporters

References